High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation Versus Dexamethasone, Cisplatin, and Cytarabine in Aggressive Non-Hodgkin's Lymphoma with Partial Response to Front-Line Chemotherapy: A Prospective Randomized Italian Multicenter Study

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 534-542

  Martelli, Maurizio ^a   Vignetti, Marco ^b   Zinzani, Pier Luigi ^b   Gherlinzoni, Filippo ^b   Meloni, Giovanna ^b   Fiacchini, Mauro ^b   De Sanctis, Vitaliana ^b   Papa, Giuseppe ^b   Martelli, Massimo F ^b   Calabresi, Federico ^b   Tura, Sante ^b   Mandelli, Franco ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW TRANSPLANTATION; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SALVAGE THERAPY; VINCRISTINE;

EID: 0030045966     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.534     Document Type: Article

References (48)

1. Longo DL, De Vita VT Jr, Duffey PL, et al: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991
2. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:596-602, 1985
3. Guglielmi C, Amadori S, Martelli M, et al: The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: Long-term results. Ann Oncol 2:365-371, 1991
4. Coiffier B, Gisselbrecht C, Herbrecht R, et al: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
5. Cabanillas F, Hagemeister FB, McLaughlin P, et al: Result of MIME salvage regimen for recurrent of refractory lymphoma. J Clin Oncol 5:407-412, 1987
6. Hayat M, Ostronoff M, Gilles E, at al: Salvage therapy with methyl-gag, high-dose ARA-C, m-AMSA, and ifosfamide (MAMI) for recurrent or refractory lymphoma. Cancer Invest 8:1-5, 1990
7. Cabanillas F, Hagemeister FB, Bodey GP, et al: IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693-697, 1982
8. Herbrecht R, Damonte JC, Dufour P, et al: Etoposide, ifosfamide and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen. Semin Oncol 19:7-10, 1992
9. Zinzani PL, Barbieri E, Visani G, et al: Ifosfamide, epirubicine, and etoposide (IEV) therapy in relapsed and refractory high grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 79:508-512, 1994
10. Philip T, Armitage JO, Spitzer G, et al: High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate grade or high grade NHL. N Engl J Med 316:1493-1498, 1987
11. Phillips GL, Fay JW, Herzig RH, et al: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75:831-838, 1990
12. Peterson FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphomas. A report of 101 cases from Seattle. J Clin Oncol 8:638-647, 1990
13. Takvorian T, Canellos GP, Ritz J, et al: Prolonged disease free survival after ABMT in patients with NHL with poor prognosis. N Engl J Med 316:1499-1505, 1987
14. De Vita VT Jr, Canellos GP, Chabner BA, et al: Advanced diffuse histiocytic lymphoma, a potential curable disease. Lancet 1:248-250, 1975
15. Skarin AT, Rosenthal DS, Moloney WC, et al: Combination chemotherapy of advanced NHL with bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). Blood 49:759-770, 1977
16. Canellos GP, Skarin AT, Klatt MM, et al: The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 24:2-7, 1987
17. Klimo P, Connors JM: Updated clinical experience with MA-COP-B chemotherapy for malignant lymphomas. Semin Hematol 24:26-34, 1987
18. Vitolo U, Bertini M, Tarella C, et al: MACOP-B tratment for advanced stage diffuse large cell lymphomas: A multicenter Italian study. Eur J Cancer Clin Oncol 25:1441-1449, 1989
19. Haq R, Sawka CA, Franssen E, et al: Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: A literature review. J Clin Oncol 12:1074-1084, 1994
20. Coiffier B, Gisselbrecht C, Vose JM, et al: Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9:211-219, 1991
21. Jagannath S, Velasquez WS, Tucker SL, et al: Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 4:859-865, 1986
22. Anderson T, De Vita VT, Simon RM, et al: Malignant lymphoma. II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 50:2708-2721, 1982
23. Armitage JO, Weisenburger DD, Hutchins M, et al: Chemotherapy for diffuse large cell lymphoma - Rapidly responding patients have more durable remissions. J Clin Oncol 4:160-164, 1986
24. Guglielmi C, Amadori S, Ruco LP, et al: Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update. Semin Oncol 14:104-109, 1987
25. Stansfeld A, Diebold J, Kapanci Y, et al: Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988
26. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
27. National Cancer Institute sponsored study of classification of non-Hodgkin' lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
28. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, World Health Organization, 1979
29. Guglielmi C, Amadori S, Anselmo AP, et al: Sequential combination chemotherapy of high grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest 5:159-169, 1987
30. Philip T, Chauvin F, Armitage J, et al: Parma interantional protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77:1587-1592, 1991
31. Meloni G, De Fabritiis P, Papa G, et al: Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse. Leuk Res 9:407-412, 1985
32. Velasquez WS, Cabanillas F, Salvador F, et al: Effective therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
33. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481,1958
34. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-38, 1977
35. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 22:209-220, 1959
36. Cox DR: Analysis of Binary Data. London, United Kingdom, Methuen, 1970
37. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
38. Mazza P, Zinzani PL, Martelli M, et al: MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma 16:457-463, 1995
39. Philip T, Hartmann O, Biron P, et al: High dose therapy and autologous bone marrow transplantation in partial response after front line induction therapy for diffuse NHL. J Clin Oncol 6:1118-1124, 1988
40. Gulati SC, Shank B, Black P, et al: Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 6:1303-1313, 1988
41. Gribben JG, Goldstone AH, Linch DC, et al: Effectiveness of high dose combination chemotherapy and ABMT for patients with NHL who are still responsive to conventional dose chemotherapy. J Clin Oncol 7:1621-1629, 1989
42. Colombat P, Gorin NC, Lemonier MP, et al: The role of autolougus bone marrow transplantation in 46 patients with non Hogkin's lymphoma. J Clin Oncol 8:630-637, 1990
43. Santini G, Congiu AM, Coser P, et al: High dose therapy with autologous bone marrow transplantation rescue (ABMT) in 100 aggressive poor prognosis non Hodgkin's lymphomas. A report of the non Hodgkin's cooperative study group. Proc Am Soc Clin Oncol 12:362, 1993 (abstr 1284)
44. Philip T, Guglielmi C, Chauvin F, et al: Autologous bone marrow transplantation (ABMT) versus (vs) conventional chemotherapy (DHAP) in relapsed non Hodgkin lymphoma (NHL): Final analysis of the PARMA randomized study (216 patients). Proc Am Soc Clin Oncol 14:390, 1995 (abstr 1220)
45. Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995
46. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 12:2543-2551, 1994
47. Gianni AM, Bregni M, Siena S, et al: 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. From the Proceedings of Conferenza Consiglio Nazionale Della Ricerche Progetto Finalizzato Applicazioni Cliniche Ricerca Oncologica "La Ricerca Oncologica in Italia," Rome, Italy, June 9-10, 1994, p. 459
48. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Factors Project. N Engl J Med 329:987-994, 1993